Neon Therapeutics Inc (NTGN) Receives $19.33 Consensus PT from Analysts

Share on StockTwits

Shares of Neon Therapeutics Inc (NASDAQ:NTGN) have been assigned a consensus recommendation of “Buy” from the eight ratings firms that are presently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $19.33.

Several analysts have issued reports on NTGN shares. Berenberg Bank started coverage on Neon Therapeutics in a research note on Wednesday, March 27th. They issued a “buy” rating and a $15.00 price target on the stock. Zacks Investment Research downgraded Neon Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, March 16th.

Neon Therapeutics stock traded down $0.28 during mid-day trading on Friday, hitting $5.30. 282 shares of the company’s stock were exchanged, compared to its average volume of 80,397. The company has a market capitalization of $153.27 million and a PE ratio of -0.98. Neon Therapeutics has a fifty-two week low of $4.20 and a fifty-two week high of $16.23.

Neon Therapeutics (NASDAQ:NTGN) last issued its quarterly earnings data on Monday, May 13th. The company reported ($0.76) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.73) by ($0.03). Equities research analysts predict that Neon Therapeutics will post -2.74 EPS for the current fiscal year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Oxford Asset Management LLP bought a new position in shares of Neon Therapeutics in the 1st quarter valued at about $549,000. ArrowMark Colorado Holdings LLC grew its holdings in shares of Neon Therapeutics by 4.9% in the 1st quarter. ArrowMark Colorado Holdings LLC now owns 947,295 shares of the company’s stock valued at $6,120,000 after acquiring an additional 44,434 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Neon Therapeutics by 153.0% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 30,308 shares of the company’s stock valued at $196,000 after acquiring an additional 18,328 shares in the last quarter. Marshall Wace North America L.P. bought a new position in shares of Neon Therapeutics in the 1st quarter valued at about $49,000. Finally, Jacobs Levy Equity Management Inc. grew its holdings in shares of Neon Therapeutics by 144.9% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 134,593 shares of the company’s stock valued at $869,000 after acquiring an additional 79,639 shares in the last quarter. 70.50% of the stock is currently owned by hedge funds and other institutional investors.

Neon Therapeutics Company Profile

Neon Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer.

Featured Story: How much can an individual set aside as a catch-up contribution?

Receive News & Ratings for Neon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Happycoin  Price Hits $0.0361 on Top Exchanges
Happycoin Price Hits $0.0361 on Top Exchanges
Quark  Price Tops $0.0093
Quark Price Tops $0.0093
CrevaCoin  Price Tops $0.0001 on Top Exchanges
CrevaCoin Price Tops $0.0001 on Top Exchanges
Bitcoin Confidential   Trading 31.2% Lower  Over Last 7 Days
Bitcoin Confidential Trading 31.2% Lower Over Last 7 Days
PPG Industries, Inc.  Given Consensus Rating of “Hold” by Brokerages
PPG Industries, Inc. Given Consensus Rating of “Hold” by Brokerages
Noble Midstream Partners LP  Given Average Rating of “Hold” by Brokerages
Noble Midstream Partners LP Given Average Rating of “Hold” by Brokerages


 
© 2006-2019 Zolmax.